- Home
- XEL vs TAK Comparison
XEL vs TAK Comparison
Compare XEL & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XEL | TAK |
|---|---|---|
| Founded | 1909 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.5B | 43.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | XEL | TAK |
|---|---|---|
| Price | $74.44 | $15.66 |
| Analyst Decision | Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $84.00 | N/A |
| AVG Volume (30 Days) | ★ 5.6M | 2.6M |
| Earning Date | 02-05-2026 | 01-29-2026 |
| Dividend Yield | 3.08% | ★ 3.39% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.27 | 0.14 |
| Revenue | $14,228,000,000.00 | ★ $29,846,840,032.00 |
| Revenue This Year | $13.16 | N/A |
| Revenue Next Year | $7.63 | $0.47 |
| P/E Ratio | ★ $22.68 | $111.82 |
| Revenue Growth | ★ 3.38 | N/A |
| 52 Week Low | $62.58 | $12.80 |
| 52 Week High | $83.01 | $15.69 |
Technical Indicators
Market Signals| Indicator | XEL | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 78.41 |
| Support Level | $72.54 | $14.43 |
| Resistance Level | $74.29 | $14.66 |
| Average True Range (ATR) | 1.27 | 0.17 |
| MACD | 0.00 | 0.13 |
| Stochastic Oscillator | 39.51 | 99.66 |
Price Performance
Historical ComparisonAbout XEL Xcel Energy Inc.
Xcel Energy manages utilities serving 3.8 million electric customers and 2.2 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan; Public Service Company of Colorado; and Southwestern Public Service Company, which serves customers in Texas and New Mexico. It is one of the largest renewable energy suppliers in the US, with more than half of its electricity sales coming from carbon-free energy.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.